PDCD1 and cancer: Based on the abovementioned data, we know that the efficacy of strategies targeting these cosignaling network receptors is increased when used in combination with other existing immune checkpoint blockade therapies, such as anti-CTLA-4 or anti-PD-1 mAbs, to treat cancer.